SymBio Pharmaceuticals Limited provided consolidated earnings guidance for the fiscal year 2022. For the year, the company expects net sales of JPY 10,992 million, operating profit of JPY 1,770 million and profit attributable to owners of parent of JPY 1,480 million or JPY 38.55 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
154 JPY | +2.67% | +2.67% | -37.65% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-37.65% | 44.87M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- 4582 Stock
- News SymBio Pharmaceuticals Limited
- SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year 2022